Adding ketamine to opioids doesn't reduce cancer pain

September 11, 2012
Adding ketamine to opioids doesn't reduce cancer pain
Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with increased toxicity, according to research published online Sept. 10 in the Journal of Clinical Oncology.

(HealthDay)—Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with increased toxicity, according to research published online Sept. 10 in the Journal of Clinical Oncology.

Janet Hardy, M.D., of the Mater Adult Hospital in South Brisbane, Australia, and colleagues conducted a multisite, dose-escalation, randomized, double-blind, placebo-controlled trial involving 185 patients with advanced cancer to evaluate the use of ketamine or placebo delivered subcutaneously over three to five days. The authors sought to determine whether the addition of ketamine to opioids improves the management of chronic uncontrolled cancer pain.

The researchers observed no significant difference between patients receiving ketamine or placebo, and it did not matter whether pain was nociceptive or neuropathic. However, there were nearly double the adverse events with ketamine compared with placebo, including a greater risk of severe adverse events (odds ratio, 1.09; 95 percent confidence interval, 1.00 to 1.18). For one positive outcome to be achieved with ketamine use, the number needed to treat was 25, compared with a number needed to harm of only six.

"This large demonstrated a strong and failed to show any additional for ketamine when delivered subcutaneously in a dose-escalating regimen over five days, while significantly increasing toxicity," the authors write.

Explore further: 'Special K' could relieve depression

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

'Special K' could relieve depression

June 7, 2012

(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new way to manage the ...

Ketamine improved bipolar depression within minutes

May 30, 2012

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Recommended for you

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

Is there a link between telomere length and cancer?

March 23, 2017

Telomeres are regions of repetitive DNA at the end of human chromosomes, which protect the end of the chromosome from damage. Whilst shorter telomeres are hypothesized biological markers of older age and have been linked ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.